Omni MedSci v. Samsung Electronics: Smartwatch Patent Suit Dismissed Without Prejudice in 44 Days
Omni MedSci, Inc. filed suit against Samsung Electronics in the Eastern District of Texas asserting US12268475B2 — a patent covering wearable health-sensing technology — against a broad range of Galaxy phones, tablets, smartwatches, and rings. The plaintiff voluntarily sought dismissal without prejudice just 44 days after filing, leaving the door open for refiling.
Broad wearable health-tech assertion ends before Samsung files any response
Filed on 5 May 2025 in the Eastern District of Texas, Omni MedSci, Inc. asserted US12268475B2 against Samsung Electronics Co. LTD., targeting an exceptionally wide product portfolio: Samsung Galaxy S, A, M, and Z series phones; Galaxy Tab A, S, and Active tablets; the Galaxy Ring; and the Galaxy Watch lineup spanning Watch through Watch Ultra. The complaint also named Fossil Gen 1–6 smartwatches, Oura Gen 1–4 rings, and multiple OnePlus watch, phone, and tablet lines, suggesting Omni MedSci was running parallel or coordinated assertion campaigns.
The case closed on 18 June 2025 — just 44 days after filing — when the court granted Omni MedSci’s own Motion to Dismiss without prejudice. The dismissal was entered under the plaintiff’s request at Dkt. No. 5, meaning Samsung had not yet filed an answer or responsive pleading at the time of dismissal. The court’s order expressly denied all other pending relief as moot and directed each side to bear its own costs, attorneys’ fees, and expenses, leaving no financial consequence for either party from this proceeding.
The speed of the voluntary dismissal — before Samsung mounted any substantive defence — is consistent with several strategic possibilities: an out-of-court licensing discussion, a decision to consolidate venues or co-defendants, or a reassessment of claim mapping against the specific accused products. Because the dismissal was without prejudice, Omni MedSci retains the right to refile the same claims against Samsung. The public record does not disclose any settlement, licence, or other resolution; the underlying commercial dispute may remain live.
Filing to Dismissed without Prejudice in 44 days
44 days — notably short for E.D. Texas patent litigation, which typically runs 2–3 years to trial
Voluntarily dismissed without prejudice: what the court’s order means for both parties
Plaintiff’s own motion ends the case before Samsung responds
A dismissal without prejudice on the plaintiff’s motion — before a defendant has answered — is a procedurally low-cost exit. The court has no discretion to convert it to a with-prejudice dismissal at this stage. Critically, no merits ruling was made: the patent’s validity, claim scope, and infringement allegations remain entirely unadjudicated. Omni MedSci retains full legal ability to refile the same claims in the same or a different court.
No merits adjudicationWithout prejudice: what the public record does — and does not — tell us
A dismissal without prejudice preserves the plaintiff’s right to refile; a dismissal with prejudice extinguishes it. The court’s order here is explicit: this is WITHOUT prejudice. Importantly, the order is silent on any settlement, licence, or covenant not to sue — meaning the public record does not confirm whether the commercial dispute has been resolved. Samsung should treat the threat of refiling as live unless it obtains written confirmation of a licence or release.
Refiling right preservedNo adverse ruling, but no certainty either — exposure to US12268475B2 persists
Samsung obtained no invalidity finding, no non-infringement ruling, and no covenant not to sue on this record. The cost-neutral outcome — each party bearing its own fees — means Samsung spent litigation resources without achieving any defensive IP milestone. If the dismissal reflects a confidential licensing arrangement, Samsung’s Galaxy Watch, Ring, and phone lines may be cleared; if not, a second complaint is a material risk. Patent professionals should monitor Omni MedSci’s filing activity across all districts.
No defensive ruling securedWearable health-sensing IP remains live: Omni MedSci’s broad assertion strategy signals portfolio pressure
The sheer breadth of accused products — spanning smartwatches, smart rings, phones, and tablets from Samsung, Fossil, Oura, and OnePlus — suggests US12268475B2 is being wielded as a platform patent capable of reading on multiple device categories. Competitors in the wearable health-tech space, including makers of PPG-based or optical sensing wearables, should treat this patent as an active enforcement risk. A swift voluntary dismissal in one proceeding often precedes coordinated refiling or a broader licensing campaign.
Broad wearable-sector exposureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Omni MedSci, Inc. | Company | Medical-technology IP licensing firm — holder of US12268475B2 covering wearable health-sensing systemsSearch in Eureka ↗ |
| Defendant | Samsung Electronics, Co. LTD. | Company | Samsung Electronics Co. LTD. — global consumer electronics manufacturer, maker of Galaxy devicesSearch in Eureka ↗ |
| Plaintiff counsel | Ty William Wilson | Attorney | Counsel for Omni MedSci, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William E. Davis , III | Attorney | Counsel for Omni MedSci, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Davis Firm PC | Law Firm | Representing Omni MedSci, Inc.Search in Eureka ↗ |
| Plaintiff law firm | The Davis Firm PC (Longview) | Law Firm | Representing Omni MedSci, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order adopts the plaintiff’s own framing verbatim — granting the motion to dismiss without prejudice and directing each party to bear its own costs. The absence of any merits language is significant: the court made no finding on patent validity, claim construction, or infringement. The ‘DENIED AS MOOT’ disposition of all other pending relief confirms that Samsung filed no substantive cross-motions before dismissal. This order creates no estoppel, no res judicata, and no claim preclusion against either party with respect to US12268475B2.
US12268475B2 — Wearable Health-Sensing Technology Patent
US12268475B2, filed under application number US18/927698, is a continuation-family patent held by Omni MedSci, Inc. covering wearable and portable systems for health monitoring — most likely involving optical or near-infrared spectroscopic sensing methods used to measure physiological parameters such as blood oxygen, glucose, or heart rate. Continuation patents of this type inherit the priority date of their parent application, potentially providing a filing date that predates many modern smartwatch and smart ring product launches.
The strategic value of this patent lies in its apparent breadth: Omni MedSci’s complaint accused devices across at least four major brands and eight product categories, from smartwatches and smart rings to smartphones and tablets — all of which embed optical health-sensing components. For OEMs, platform vendors, and PPG or SpO2 sensor suppliers serving the wearable market, US12268475B2 represents a credible enforcement risk that has not been extinguished by this dismissal. Any entity shipping health-sensing wearables into the US market should assess freedom to operate against this patent family before the next complaint is filed.
Should you run an FTO analysis against US12268475B2?
If your product roadmap includes optical health-sensing wearables — smartwatches, fitness bands, smart rings, or smartphones with embedded PPG, SpO2, or spectroscopic sensors — US12268475B2 is a patent your IP team should have mapped. Omni MedSci’s willingness to name eight product categories across four major brands in a single complaint signals an assertion posture broad enough to reach most players in the wearable health-tech supply chain, including component makers and platform integrators, not just OEM device manufacturers.
PatSnap Eureka’s FTO Search Agent can build a claim-by-claim map of US12268475B2 against your specific product architecture in a fraction of the time of manual analysis. Eureka cross-references prosecution history amendments, continuation family members, and related prior art — so your team understands not just whether claims read on your device, but where the boundaries were drawn during prosecution and which arguments are already foreclosed. Start your FTO analysis before Omni MedSci identifies your products as the next accused line.
Run a freedom-to-operate analysis on US12268475B2 to assess your product’s exposure
Run FTO in Eureka →Similar Wearable Health-Tech Patent Cases in E.D. Texas
Cases involving wearable optical-sensing and health-monitoring patents litigated in the Eastern District of Texas — including comparable voluntary dismissal patterns and continuation-family assertions.
What this case signals for the wearable health-tech IP landscape
Omni MedSci’s rapid voluntary dismissal in E.D. Texas is a strategic data point — not a resolution — for anyone operating in the wearable sensing space.
Monitor Omni MedSci’s docket activity across all federal districts
A without-prejudice dismissal this early typically reflects a tactical repositioning, not a case won. Competitors and Samsung’s counsel should track new filings by Omni MedSci in other districts — particularly W.D. Texas, D. Delaware, and N.D. California — where the same patent may be re-asserted. PatSnap Litigation Monitor can alert on new Omni MedSci filings in real time.
US12268475B2 covers a broad product surface — map your exposure now
The accused product list spans optical health-sensing wearables, smartphones with embedded sensors, and smart rings. Any OEM or component supplier whose devices perform continuous health monitoring via optical or spectroscopic sensing should conduct a freedom-to-operate analysis against US12268475B2 before Omni MedSci refiles or extends its campaign to new defendants.
Omni v Samsung — key questions answered
The case was dismissed without prejudice on 18 June 2025, 44 days after filing. Plaintiff Omni MedSci filed the motion to dismiss itself at Dkt. No. 5. The court granted it, ordered each party to bear its own costs, and denied all other pending relief as moot. No merits ruling was made on patent validity or infringement.
Omni MedSci asserted US12268475B2, filed under application number US18/927698. The patent relates to wearable health-sensing technology. It was asserted against Samsung Galaxy phones (A, M, S, Z series), Galaxy tablets (Tab A, Tab S, Tab Active), the Galaxy Ring, and the full Galaxy Watch lineup, as well as Fossil smartwatches, Oura rings, and OnePlus devices.
No. A dismissal without prejudice carries no merits determination. Samsung received no finding of non-infringement, no invalidity ruling, and no covenant not to sue. The order creates no estoppel. Omni MedSci retains the legal right to refile the same claims against Samsung or any other defendant at any time before the applicable statute of limitations expires.
The public record does not disclose the reason. Possible explanations include: an out-of-court licensing or settlement discussion, a decision to refile in a different venue or consolidate with other defendants, or a reassessment of claim mapping. The cost-neutral dismissal order — each party bearing its own fees — does not confirm any financial resolution. The underlying IP dispute over US12268475B2 should be treated as potentially live.
The complaint accused Samsung Galaxy A, M, S, and Z series phones; Galaxy Tab A, S, and Active tablets; the Galaxy Ring; and Galaxy Watch through Galaxy Watch Ultra. Additional accused products included Fossil Gen 1–6 smartwatches, Oura Gen 1–4 smart rings, and OnePlus watches, phones (OnePlus 6 through OnePlus Open and Nord N30), and tablets (OnePlus Pad and Pad 2).
PatSnap Eureka searches patents and litigation data to answer instantly.